AMENDMENT NO. 1 TO PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • December 31st, 2018 • Neurotrope, Inc. • Pharmaceutical preparations • New York
THIS AMENDMENT, dated as of December 20, 2018 (this “Amendment”), between GP Nurmenkari Inc., a registered broker-dealer and member of the Financial Industry Regulatory Authority (“FINRA”) (hereinafter referred to as the “Placement Agent”) and Neurotrope Inc., a publicly traded Nevada corporation (the “Company”)
AMENDMENT NO. 1 TO ADVISORY CONSULTING AGREEMENTAdvisory Consulting Agreement • December 31st, 2018 • Neurotrope, Inc. • Pharmaceutical preparations • New York
AMENDMENT NO. 1 TO ADVISORY CONSULTING AGREEMENT (the “Amendment”) dated as of December 21, 2018, by and between KATALYST SECURITIES LLC, a broker dealer registered with the Financial Industry Regulatory Authority (“FINRA”) (“Katalyst”) and NEUROTROPE, INC., a publicly traded company incorporated in the State of Nevada (the “Company”).
AMENDMENT NO. 1 TO ADVISORY CONSULTING AGREEMENTAdvisory Consulting Agreement • December 31st, 2018 • Neurotrope, Inc. • Pharmaceutical preparations • New York
AMENDMENT NO. 1 TO ADVISORY CONSULTING AGREEMENT (the “Amendment”) dated as of December 31, 2018, by and between MAXIM GROUP LLC, a broker dealer registered with the Financial Industry Regulatory Authority (“FINRA”) (“Maxim”) and NEUROTROPE, INC., a publicly traded company incorporated in the State of Nevada (the “Company”).
